Study (year) |
Design |
Patients (n) |
Regimen |
Duration (days) |
Clinical outcomes (%) |
Microbiology outcomes (%) |
Ref. |
Levofloxacin
|
Masterton and Burley (2001) |
R, db, mc, mn |
530 |
L: 500 mg q.d. |
5 |
L: 82.8 (197/238)†
|
L: 82.1 (92/112)†
|
[37] |
L: 500 mg q.d. |
7 |
L: 84.8 (207/244) 95% CI: -9.1–4.9 (day 14) |
L: 83.2 (84/101) (day 14) |
Martinez et al. (2005) |
R, b, mc |
394 uncomplicated |
L: 750 mg q.d. |
3 |
L: 93.0 |
L: 93.8 (75/80) |
[38] |
Az: 500 mg q.d. 250 mg q.d. |
5 |
Az: 90.1% 95% CI: -9.6–3.8 |
Az: 90.1% 95% CI: -9.6–3.8 |
369 complicated |
L: 750 mg q.d. |
5 |
L: 79.2 |
L: 81.4 (70/86) |
AC: 875 mg/125 mg b.i.d. |
10 |
AC: 81.7 95% CI: -7.8–12.9 |
AC: 79.8 (71/89) 95% CI: -13.9–10.7 |
Grossman et al. (2006) |
R, mc |
369 |
L: 750 mg q.d. |
5 |
|
L: 97.1 (297/306) |
[26] |
AC: 875/125 mg b.i.d. |
10 |
AC: 90.6 (242/267) (p < 0.001) |
Moxifloxacin
|
Chodosh et al. (2000) |
R, db |
936 |
M: 400 mg q.d. M: 400 mg q.d. CL: 500 mg b.i.d. |
5 10 10 |
M: 94 (127/135) M: 94 (136/144) CL: 95 (121/127) (days 10–16) |
M: 94 (127/135) M: 95 (138/145) CL: 91 (115/127) (days 10–16) |
[39] |
M: 94 (127/135) M: 96 (134/140) CL: 96 (118/123) (days 17–27) |
M: 89 (127/143) M: 91 (135/148) CL: 85 (110/129) (days 17–27) |
M: 95 (274/288)‡
M: 95 (266/281) CL: 94 (268/286) (days 10–16) |
M: 93 (142/152)‡
M: 95 (156/165) CL: 90 (130/144) (days 10–16) |
M: 94 (242/256) M: 97 (250/258) CL: 95% (232/245) (days 17–27) |
M: 87 (130/149) M: 91 (144/159) CL: 83 (113/136) (days 17–27) |
Urueta-Robledo et al. (2006) |
R, db, mc, mn |
563 |
M: 400 mg q.d. |
5 |
M: 91 (201/221) |
M: 92.8(128/138) |
[40] |
L: 500 mg q.d. |
7 |
L: 94 (203/216) |
L: 93.8 (121/129) |
Schaberg et al. (2001) |
R, nb, mc, mn |
575 |
M: 400 mg q.d. AC: 625 mg t.i.d. |
5 7 |
M: 96.2 (251/261) AC: 91.6 (230/251) 95% CI: 0.4–8.7% (day 14) |
M: 87.7 (64/73) AC: 89.6 (60/67) (day 14) |
[27] |
M: 89.4 (227/254) AC: 87.5 (217/248) 95% CI: -3.5–7.5 (days 28–35) |
M: 78.2 (68/87) AC: 80.5 (62/77) (days 28–35) |
M: 92.5 (270/292)‡
AC: 85.2 (241/283) 95% CI: 2.2–12.54 (day 14) |
M: 87.7 (64/73)‡
AC: 89.6 (60/67) (day 14) |
M: 88.4 (244/276) AC: 85.0 (226/266) 95% CI: -2.1–9.2 (days 28–35) |
M: 78.2 (68/87) AC: 80.5 (62/77) (days 28–35) |
Starakis et al. (2004) |
R, nb |
153 |
M: 400 mg q.d. AC: 625 mg t.i.d. |
5 7 |
M: 88.6 (70/79) AC: 89.2 (66/74) (day 14) |
M: 90.9 (20/22) AC: 90.0 (18/20) (day 14) |
[28] |
M: 90.0 (63/70) AC: 89.4 (59/66) (days 28–35) |
M: 90.0 (18/20) AC: 88.9 (16/18) (days 28–35) |
DeAbate et al. (2000) |
R, db, mc |
567 |
M: 400 mg q.d. Az: 500 mg q.d. 250 mg q.d. |
5 1 4 |
M: 88 (194/221) Az: 88 (214/243) |
M: 95 Az: 94 |
[29] |
Grassi et al. (2002) |
R, mc |
476 |
M: 400 mg q.d. Cx: 1 g q.d. |
5 7 |
M: 90.6 (193/213)†
Cx: 89.0 (187/210) 95% CI: 0.634–2.258 |
M: 91.7 (33/36) Cx: 93.3 (28/30) |
[30] |
Wilson et al. (1999) |
R, db, mc, mn |
750 |
M: 400 mg q.d. CL: 500 mg b.i.d. |
5 7 |
M: 89 (287/322)‡§
CL: 88 (289/327) 95% CI: -3.9–5.8 (day 14) |
M: 77 (89/115) CL: 62 (71/114) 95% CI: 3.6–26.9 (day 14) |
[31] |
M: 89 (256/287) CL: 89 (257/289) (days 21–28) |
M: 80 (71/89) CL: 78 (55/71) (days 21–28) |
Wilson et al. (2004) |
R, db, mc, mn |
730 |
M: 400 mg q.d. A: 500 mg t.i.d. CL: 500 mg b.i.d. Cf: 250 mg b.i.d. |
5 7 7 7 |
M: 87.2 (239/274)†
A: 81.5 CL: 87.4 Cf: 83.8 |
M: 91.5 (65/71)†
A + CL + Cf: 81% (64/79) |
[32] |
Combined all three comparators 95% CI: -3.0–8.5 |
Combined all three comparators 95% CI: 0.4–22.1 |
M: 87.6 (310/354)‡
A: 83.0 CL: 84.2 Cf: 82.2 |
M: 76.8 (86/112)‡
A + CL + Cf: 67.5 (81/120) |
Combined all three comparators 95% CI: -0.7–9.5 |
Combined all three comparators 95% CI: -1.8–20.4 |
Wilson et al. (2006) |
R, db, mc, mn |
730 |
M: 400 mg q.d. A: 500 mg t.i.d. CL: 500 mg b.i.d. Cf: 250 mg b.i.d. |
5 7 7 7 |
71 (251/354)§
63 (487/730) (p = 0.020) |
|
[41] |
Zervos et al. (2007) |
R, mc |
342 |
M: 400 mg q.d. Az: 500 mg q.d. |
5 3 |
M: 90 (149/165)†
Az: 90 (147/164) (days 10–12) |
M: 84 Az: 93 (days 10–12) |
[33] |
M: 82 (132/162)†
Az: 81 (133/164) (days 22–26) |
M: 73 (40/55) Az: 89 (42/46) (days 22–26) |
Gemifloxacin
|
Sethi et al. (2004) |
R, db |
360 |
Ge: 320 mg q.d. L: 500 mg q.d. |
5 7 |
Ge: 97.5 (156/160)†
L: 93.5 (145/155) 95% CI: -0.61–8.51 (days 5–7) |
Ge: 87.5†
L: 90.4 (days 5–7) |
[42] |
Ge: 88.2 (134/152) L: 85.1 (126/148) 95% CI: -4.67–10.72 (days 14–21) |
Ge: 78.4 L: 85.7 (days 14–21) |
Ge: 83.7 (123/147) L: 78.4 (109/139) 95% CI: -3.83–14.34 (days 28–35) |
Ge: 77.8 L: 70.5 (days 28–35) |
Ge: 94.0 (171/182)‡
L: 88.8 (158/178) 95% CI: -0.60–10.98 (days 5–7) |
Ge: 81.8‡
L: 86.7 (days 5–7) |
Ge: 85.2 (155/182) L: 78.1 (139/148) 95% CI: -0.9–15.05 (days 14–21) |
Ge: 75.0 L: 80.0 (days 14–21) |
Ge: 80.8 (123/147) L: 70.8 (109/139) 95% CI: 1.18–18.78 (days 28–35) |
Ge: 75.0 L: 65.0 (days 28–35) |
Wilson et al. (2002) |
R, db, mc, mn |
712 |
Ge: 320 mg q.d. CL: 500 mg b.i.d. |
5 7 |
Ge: 85.4 (300/351)†
CL: 84.6 (303/358) 95% CI: -5.0–6.6 |
Ge: 86.7 (39/45)†
CL: 73.1 (38/52) 95% CI: -2.0–29.2 |
[7, 43] |
El Moussaoui et al. (2008) |
PP population Ge: 79.5 (279/351)‡
CL: 78.2 (280/358) ITT population (days 13–24) |
Ge: 75.4 (43/57)‡
CL: 63.6 (42/66) 95% CI: -4.3–27.9 (days 13–24) |
Wilson et al. (2003) |
R, db, mc, mn |
272 |
Ge: 320 mg q.d. Cx: 1 g iv. q.d. Cf: 500 mg b.i.d. |
5 3 7 |
Ge: 86.8 (105/121)†
Cx/Cf: 81.3 (91/112) 95% CI: -3.9–14.9 |
Ge: 62.5 (30/48)†
Cx + Cf: 60.8 (31/51) 95% CI: -17.4–20.9 |
[34] |
PP population 82.6 (114/138)†
72.1 (98/136) 95% CI: 0.7–20.4 ITT population (2–4 days post-therapy) |
File et al. (2000) |
R, db, mc |
600 |
Ge: 320 mg q.d. AC: 500/125 mg t.i.d. |
5 7 |
Ge: 93.6 AC: 93.2 95% CI: -3.9–4.6 |
Ge: 90.9 AC: 79.5 95% CI: -3.3–26.0 |
[35] |
Ball et al. (2001) |
R, db, mn |
617 |
Ge: 320 mg q.d. T: 200 mg q.d. |
5 5 |
Ge: 91.5†
T: 87.6 |
Ge: 86.8†
T: 82.4 |
[44] |
Comments